<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurotherapeutics</journal-id><journal-id journal-id-type="iso-abbrev">Neurotherapeutics</journal-id><journal-id journal-id-type="pmc-domain-id">1472</journal-id><journal-id journal-id-type="pmc-domain">neurother</journal-id><journal-title-group><journal-title>Neurotherapeutics</journal-title></journal-title-group><issn pub-type="ppub">1933-7213</issn><issn pub-type="epub">1878-7479</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9294128</article-id><article-id pub-id-type="pmcid-ver">PMC9294128.1</article-id><article-id pub-id-type="pmcaid">9294128</article-id><article-id pub-id-type="pmcaiid">9294128</article-id><article-id pub-id-type="pmid">35391662</article-id><article-id pub-id-type="doi">10.1007/s13311-022-01228-5</article-id><article-id pub-id-type="publisher-id">1228</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Current Perspectives</subject></subj-group></article-categories><title-group><article-title>Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1012-6550</contrib-id><name name-style="western"><surname>Markowicz-Piasecka</surname><given-names initials="M">Magdalena</given-names></name><address><email>magdalena.markowicz@umed.lodz.pl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Markiewicz</surname><given-names initials="A">Agata</given-names></name><address><email>agata.markiewicz1@stud.umed.lodz.pl</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dar&#322;ak</surname><given-names initials="P">Patrycja</given-names></name><address><email>patrycja.darlak@stud.umed.lodz.pl</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sikora</surname><given-names initials="J">Joanna</given-names></name><address><email>joanna.sikora@umed.lodz.pl</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Adla</surname><given-names initials="SK">Santosh Kumar</given-names></name><address><email>santosh.adla@uef.fi</email><email>santosh.adla@uochb.cas.cz</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bagina</surname><given-names initials="S">Sreelatha</given-names></name><address><email>sreelatha.bagina@crl.com</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huttunen</surname><given-names initials="KM">Kristiina M.</given-names></name><address><email>kristiina.huttunen@uef.fi</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.8267.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2165 3025</institution-id><institution>Laboratory of Bioanalysis, Department of Pharmaceutical Chemistry, Drug Analysis and Radiopharmacy, </institution><institution>Medical University of Lodz, </institution></institution-wrap>ul. Muszy&#324;skiego1, 90-151 Lodz, Poland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.8267.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2165 3025</institution-id><institution>Students Research Group, Laboratory of Bioanalysis, Department of Pharmaceutical Chemistry, Drug Analysis and Radiopharmacy, </institution><institution>Medical University of Lodz, </institution></institution-wrap>ul. Muszy&#324;skiego 1, 90-151 Lodz, Poland </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.8267.b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2165 3025</institution-id><institution>Department of Bioinorganic Chemistry, </institution><institution>Medical University of Lodz, Medical University of Lodz, </institution></institution-wrap>ul. Muszy&#324;skiego1, 90-151 Lodz, Poland </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.9668.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 0726 2490</institution-id><institution>School of Pharmacy, Faculty of Health Sciences, </institution><institution>University of Eastern Finland, </institution></institution-wrap>Yliopistonranta 1C, POB 1627, 70211 Kuopio, Finland </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.418095.1</institution-id><institution-id institution-id-type="ISNI">0000 0001 1015 3316</institution-id><institution>Institute of Organic Chemistry and Biochemistry (IOCB), </institution><institution>Czech Academy of Sciences, </institution></institution-wrap>Flemingovo Namesti 542/2, 160 00 Prague, Czech Republic </aff><aff id="Aff6"><label>6</label>Charles River Discovery Research Services Finland Oy, Neulaniementie 4, 70210 Kuopio, Finland </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>4</month><year>2022</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2022</year></pub-date><volume>19</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">412688</issue-id><fpage>942</fpage><lpage>976</lpage><history><date date-type="accepted"><day>24</day><month>3</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>01</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-26 08:25:17.773"><day>26</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The American Society for Experimental NeuroTherapeutics, Inc. 2022</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="13311_2022_Article_1228.pdf"/><abstract id="Abs1"><p id="Par1">One of the greatest challenges with successful pharmaceutical treatments of central nervous system (CNS) diseases is the delivery of drugs into their target sites with appropriate concentrations. For example, the physically tight blood&#8211;brain barrier (BBB) effectively blocks compounds from penetrating into the brain, also by the action of metabolizing enzymes and efflux transport mechanisms. However, many endogenous compounds, including both smaller compounds and macromolecules, like amino acids, sugars, vitamins, nucleosides, hormones, steroids, and electrolytes, have their peculiar internalization routes across the BBB. These delivery mechanisms, namely carrier-mediated transport and receptor-mediated transcytosis have been utilized to some extent in brain-targeted drug development. The incomplete knowledge of the BBB and the smaller than a desirable number of chemical tools have hindered the development of successful brain-targeted pharmaceutics. This review discusses the recent advancements achieved in the field from the point of medicinal chemistry view and discusses how brain drug delivery can be improved in the future.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s13311-022-01228-5.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Brain-blood barrier</kwd><kwd>Prodrug approach</kwd><kwd>Carrier-mediated transport</kwd><kwd>Receptor-mediated transport</kwd><kwd>Drug delivery</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100005888</institution-id><institution>Uniwersytet Medyczny w Lodzi</institution></institution-wrap></funding-source><award-id>503/3-015-01/503-31-001-19-00</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002341</institution-id><institution>Academy of Finland</institution></institution-wrap></funding-source><award-id>294227</award-id><principal-award-recipient><name name-style="western"><surname>Huttunen</surname><given-names>Kristiina M.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The American Society for Experimental NeuroTherapeutics, Inc. 2022</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>